Skip to main content
. 2024 Jun 27;15(3):841–850. doi: 10.21037/jgo-24-295

Figure 3.

Figure 3

Frequency of 30-day complications between two groups. NS, not significant; nICT, neoadjuvant immunotherapy combined with chemotherapy; nICRT, neoadjuvant immunotherapy combined with chemoradiotherapy.